Enzymotec Ltd. Announces Publication of Clinical Study Results on Crying Reduction Following Usage of INFAT(R) in Infants
07 July 2014 - 10:38PM
Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and
marketer of innovative bio-active lipid ingredients, announced
today on publication of its clinical study results evaluating the
effect of INFAT® usage on crying in healthy infants (link to the
journal: http://www.biomedcentral.com/1471-2431/14/152).
The article manuscript titled, "Reduced crying in term infants
fed high beta-palmitate formula: a double-blind randomized clinical
trial" was published in the peer-reviewed journal "BMC Pediatrics."
The study was conducted by Dr. Ita Litmanovitz from Meir Medical
Center, Kfar Saba, Israel.
Enzymotec's 12-week study investigated the effects of feeding
infants with a formula containing INFAT®, high sn-2 palmitate fat
ingredient, on infants crying. The clinical trial included 83 term
infants, 58 formula-fed and 25 breast-fed. The formula fed infants
were assigned to either a sn-2 palmitate group receiving formula
with INFAT®, or a control group receiving formula using standard
vegetable oil blend. Infants' crying was analyzed based on data
from parents' detailed diaries at 6 and 12 weeks postnatal age.
"Although crying is a common spontaneous behavior, it can induce
parental concern. Our study indicates that formula containing
INFAT® affects infant crying patterns. The results of the study
indicate significantly lower crying duration, primarily during
afternoon and evening hours, in the formula with INFAT® compared to
a standard vegetable oil control infant formula," said Dr. Fabiana
Bar-Yoseph of Enzymotec infant nutrition R&D.
"We are very pleased with the results of the study, which
further demonstrate the positive effects of INFAT® consumption for
infants, thereby improving the well-being of formula-fed infants
and their parents," said Dr. Ariel Katz, President and Chief
Executive Officer of Enzymotec Ltd.
INFAT® is sold and marketed by Advanced Lipids, a joint venture
of AAK and Enzymotec. It is a clinically-proven sn-2 palmitate fat
ingredient that more closely resembles the structure and properties
of human milk fat.
About Enzymotec Ltd.
Enzymotec Ltd. is a leading global supplier of specialty
lipid-based products and solutions. The Company develops,
manufactures and markets innovative bio- active lipid ingredients,
as well as final products, based on sophisticated processes and
technologies. For more information, visit www.enzymotec.com.
About Advanced Lipids AB
Advanced Lipids is a joint venture of AAK and Enzymotec that was
established for the marketing, sale and distribution of INFAT® to
the infant nutrition industry. INFAT® is produced in AAK's state of
the art production facilities in Sweden based on proprietary
enzymatic technology developed by Enzymotec. For more information,
visit www.advancedlipids.com.
Forward Looking Statements
This release may contain forward-looking statements, which
express the current beliefs and expectations of Company management.
Such statements involve a number of known and unknown risks and
uncertainties that could cause our future results, performance or
achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. Important factors that could cause or contribute to
such differences the following risks: we depend on third parties to
obtain raw materials, in particular krill, necessary for the
production of our products; a high proportion of the sales of our
INFAT® product is sold to end users by a single company in China;
we are subject to a degree of customer concentration and our
customers do not enter into long-term purchase commitments with us;
we may be required to pay royalties on sales of our krill products
in North America and Australia; we have in the past, and may in the
future, become subject to litigation regarding intellectual
property rights or other matters; our offering of products as
''medical foods'' in the United States may be challenged by
regulatory authorities; we rely on our Swedish joint venture
partner to manufacture INFAT®, and certain matters related to the
joint venture are the subject of disagreement; we are dependent on
a single facility that houses the majority of our operations; we
may be impacted by delays in manufacturing as we expand our
capacity; we may not be able to expand our production or processing
capabilities or satisfy growing demand; our gross profits may be
adversely affected if we are only able to obtain lower quality
krill meal; our ability to obtain krill may be affected by
conservation regulation or initiatives; our product development
cycle is lengthy and uncertain, and our development or
commercialization efforts for our products may be unsuccessful; we
are subject to significant and increasing government regulations
regarding the sale and marketing of our products; we may not be
able to protect our proprietary technology or prevent its
unauthorized use by third parties; and other factors discussed
under the heading "Risk Factors" in the Company's Form 20-F filed
with the Securities and Exchange Commission on February 13, 2014.
Forward-looking statements in this release are made pursuant to the
safe harbor provisions contained in the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
made only as of the date hereof, and the Company undertakes no
obligation to update or revise the forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACT: ICR, LLC
Katie Turner
646-277-1228
-or-
John Mills
310-954-1105
John.Mills@icrinc.com
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024